CorEvitas
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
The objective of the CorEvitas Multiple Sclerosis (MS) Registry is to create a national cohort of patients with MS. Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of MS. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the prevalence and incidence of comorbidities and adverse events, medication utilization patterns and patient productivity measures. The design is a p…
Inclusion Criteria: 1. Has a diagnosis of MS at the time of enrollment. 2. Age 18 years or older at the time of enrollment. 3. Willing to provide Personal Information. 4. Initiating (prescribed or starting) an Eligible Medication for the treatment of MS at the enrollment visit. Exclusion Criteria: 1\) Is participating or planning to participate in a double-blind randomized trial for an MS drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.